NCT00172419View on ClinicalTrials.gov

The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.

NACompletedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Hyperlipidemia

Interventions

DRUG

Atorvastatin

Atorvastatin, 40 mg/day for 12 weeks

Trial Locations (1)

10012

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

collaborator

Pfizer

INDUSTRY

lead

National Taiwan University Hospital

OTHER

NCT00172419 - The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients. | Biotech Hunter | Biotech Hunter